Notice
Road and parking lot construction in Madison, Wis. may result in travel delays and route changes to UW Health clinic and hospital locations. Please plan accordingly.Read more
About
Dr. Joseph P. Connor completed his medical degree at the University of Cincinnati College of Medicine. He received residency training in Obstetrics and Gynecology at Northwestern University followed by sub- specialty fellowship training in Gynecologic Oncology at the University of Iowa. He is a physician-scientist whose primary research focus is on immune mechanisms of disease as it relates to gynecologic cancers. Dr. Connor is currently a member of the UW Carbone Cancer Center's Experimental Therapeutics Program. He is the Director of the UWCCC Gynecologic Cancer Disease-Oriented Working Group. This group works on research efforts to treat female pelvic cancers.
Languages spoken
- English
University affiliation
Practice locations
Education & credentials
Board certifications
- Obstetrics and Gynecology
- Gynecologic Oncology
- Pathology
Medical School
- University of Cincinnati College of Medicine, Cincinnati, OH
Fellowships
Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
Residencies
- Northwestern Memorial Hospital, Chicago, IL
- University of Cincinnati Medical Center, Cincinnati, OH
Specialties
Additional conditions and treatments
- Robotic hysterectomy
Research & publications
Dr. Connor is the primary investigator on two current clinical trials of novel immune based therapies for gynecologic cancers. He is also co-investigator on several grants with Dr. Manish Patankar, a PhD scientist in the Cancer Center. His main research interests are: the development of immunotherapy for gynecologic malignancies via phase I and phase II clinical trials, both investigator-initiated and via the Gynecologic Oncology Group; mechanisms of immune evasion in cancer; and improving the clinical use of the CA125 blood test for ovarian cancer by researching the function of CA125 in ovarian cancer - in particular, CA125's effects on immune cell function in women with ovarian cancer and its ability to facilitate metastasis by interaction with other cancer-associated molecules that allow attachment of ovarian tumor cells.
